Small study tests drug interaction in advanced cancer patients
NCT ID NCT05063318
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lurbinectedin and itraconazole
What this could lead to
If successful, this could help doctors understand how to safely combine lurbinectedin with other drugs, potentially improving treatment options for advanced solid tumors.
What could go wrong
This is a very early, small Phase 1 study with only 14 participants. It focuses on drug levels, not on treating the cancer itself, so it may not lead to any direct benefit for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital HM Sanchinarro
Madrid, 28050, Spain